Early outcomes of Pyrocardan® implants for trapeziometacarpal osteoarthritis.
The aim of this retrospective study was to assess the early outcomes of trapeziometacarpal osteoarthritis treatment using Pyrocardan® implants in patients with early Eaton (stage I and II) osteoarthritis. We analyzed the results of 27 patients, with a median age of 59 years (range, 34-78 years) and a mean follow-up of 24 months (range, 12-41). The level of satisfaction was assessed using a postoperative questionnaire. Twenty patients mentioned having improvements in their activities of daily living, 20 patients were satisfied with the outcomes of surgery, and 19 patients would consider undergoing the procedure a second time. Five patients needed reoperation for complications, including persistent pain, grinding, or implant dislocation. Pyrocardan® implants may be a valuable temporary therapy as more conventional arthroplasty techniques are still feasible in case of failure. However, multicenter randomized controlled trials with a longer follow-up are needed to assess the long-term outcomes.